Arca
Skip to content
Tools
Tools

CA1: Carbonic anhydrase 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the reversible hydration of carbon dioxide.

  • Drugs that act on it: 5
  • Approved: 4
  • In phases 1 to 3: 1
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CA1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved4

  • Acetazolamide
  • Methocarbamol
  • Methazolamide
  • Dichlorphenamide

Phase 31

  • Polmacoxib

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • CrystalGenomics, Inc.120%
      • Incannex Healthcare Ltd120%

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule5100%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Carbonic anhydrase I inhibitor.
      AcetazolamideApprovedIncannex Healthcare LtdSmall moleculeInhibitor—43Boxed warning
      MethocarbamolApprovedEndo InternationalSmall moleculeInhibitor—12—
      MethazolamideApprovedPfizerSmall moleculeInhibitor—1—
      DichlorphenamideApprovedXeris PharmaceuticalsSmall moleculeInhibitor—0—
      PolmacoxibPhase 3CrystalGenomics, Inc.Small moleculeInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 17 in all, from ClinicalTrials.gov.
      Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart FailureAcetazolamidePhase 4Active, not recruitingUniversidade do Porto2026-11-09
      Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 DiabetesAcetazolamidePhase 2Not yet recruitingUniversity Health Network, Toronto2026-10-29
      Suzetrigine for Analgesiain Arthroscopic Rotator Cuff RepairMethocarbamolPhase 4Not yet recruitingUniversity of Alabama at Birmingham2026-10-08
      ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.AcetazolamidePhase 3Not yet recruitingUniversity Hospital, Montpellier2026-07-30
      Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary ManagementAcetazolamideNot applicableActive, not recruitingSohag University2026-07-16
      DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.AcetazolamidePhase 2RecruitingIncannex Healthcare Ltd2026-06-09
      Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney InjuryMethocarbamolPhase 2RecruitingRiver 2 Renal Corp.2026-06-04
      TACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart FailureAcetazolamidePhase 4Not yet recruitingLucrecia Maria Burgos2026-05-18
      The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High AltitudeAcetazolamideEarly phase 1Active, not recruitingUniversity of California, Riverside2026-04-08
      Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging StudyAcetazolamide—RecruitingCopenhagen University Hospital, Rigshospitalet2026-03-19
      Plasma Relaxin Measurement Based on Endometrial Preparation for Embryo TransferMethocarbamol—Not yet recruitingHospices Civils de Lyon2026-03-17
      Examining Analgesic Synergy and Efficacy in Trauma CareMethocarbamolPhase 4Not yet recruitingWake Forest University Health Sciences2026-02-27
      Relaxin Therapy for Atrial FibrillationMethocarbamolPhase 1 / Phase 2Not yet recruitingDeeptankar DeMazumder2026-01-22
      An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServiceMethocarbamolPhase 3Not yet recruitingUniversity of California, San Francisco2025-12-22
      Progressive Relaxation for COPD: Effects on Insomnia and SatisfactionMethocarbamolNot applicableActive, not recruitingCeylan Aksoy2025-04-18
      Reduce Opiate Exposure With ACL SurgeryMethocarbamolPhase 3Enrolling by invitationCampbell Clinic2024-08-19
      Use of Methazolamide to Lower Intraocular PressureMethazolamidePhase 4Active, not recruitingUniversity of Colorado, Denver2022-08-11

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Altitude sickness
      0.59
      Angle-closure glaucoma
      0.59
      Edema
      0.59
      Seizure
      0.59
      Congestive heart failure
      0.37
      Rheumatic disorder
      0.37
      Pseudotumor cerebri
      0.35

      Genes and Related Targets

      Complexes and families that share a gene with this target
      Genes
      CA1

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL261, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00915, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.